491 reports of this reaction
1.5% of all AMPHOTERICIN B reports
#15 most reported adverse reaction
RESPIRATORY FAILURE is the #15 most commonly reported adverse reaction for AMPHOTERICIN B, manufactured by Astellas Pharma US, Inc.. There are 491 FDA adverse event reports linking AMPHOTERICIN B to RESPIRATORY FAILURE. This represents approximately 1.5% of all 32,295 adverse event reports for this drug.
Patients taking AMPHOTERICIN B who experience respiratory failure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RESPIRATORY FAILURE is a less commonly reported adverse event for AMPHOTERICIN B, but still significant enough to appear in the safety profile.
In addition to respiratory failure, the following adverse reactions have been reported for AMPHOTERICIN B:
The following drugs have also been linked to respiratory failure in FDA adverse event reports:
RESPIRATORY FAILURE has been reported as an adverse event in 491 FDA reports for AMPHOTERICIN B. This does not prove causation, but indicates an association observed in post-market surveillance data.
RESPIRATORY FAILURE accounts for approximately 1.5% of all adverse event reports for AMPHOTERICIN B, making it a notable side effect.
If you experience respiratory failure while taking AMPHOTERICIN B, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.